Patents Assigned to University College Cardiff
-
Publication number: 20240092873Abstract: The invention relates to an anti-viral composition comprising at least one, and ideally a plurality of, monoclonal antibodies, or fragments thereof; an immunogenic agent, vaccine or pharmaceutical composition comprising the afore anti-viral composition; said anti-viral composition, immunogenic agent, vaccine or said pharmaceutical composition for use in the treatment of or prevention of a viral infection; use of said anti-viral composition in the manufacture of a medicament to treat or prevent a viral infection; a combination therapeutic for use in the treatment or prevention of a viral infection comprising said anti-viral composition, immunogenic agent, vaccine or pharmaceutical composition in combination with at least one other therapeutic agent; and a method of treating or preventing a viral infection comprising administering said anti-viral composition, immunogenic agent, vaccine or said pharmaceutical composition to an individual having, or suspected of having, a viral infection.Type: ApplicationFiled: January 27, 2022Publication date: March 21, 2024Applicant: University College Cardiff Consultants LimitedInventors: Richard Stanton, Edward Chung Yern Wang
-
Publication number: 20230416827Abstract: There is provided a method for distinguishing between sepsis and systemic inflammatory response syndrome (SIRS) in a patient, comprising: (i) determining the amount of one or more biomarker for sepsis, and one or more biomarker for SIRS in a sample obtained from a patient, wherein the one or more biomarker for sepsis is selected from the group consisting of: ITGB3, ITGA2B, MYL9, LCN2, TREML1, LCN15, CMTM5, PPBP, and PF4; and the one or more biomarker for SIRS is selected from the group consisting of: PLA2G7, ARHGEF10L, MYCL, TGFBI, and GPR124, (ii) comparing the amount of the one or more biomarker for sepsis determined in said sample in (i) to a corresponding reference value representative of a healthy individual, (iii) comparing the amount of the one or more biomarker for SIRS determined in said sample in (i) to a corresponding reference value representative of a healthy individual; wherein the patient is diagnosed as having sepsis, when an increase is observed in the one or more biomarker for sepsis, and noType: ApplicationFiled: May 12, 2023Publication date: December 28, 2023Applicants: The Secretary of State for Health, University College Cardiff Consultants LimitedInventors: Judith Hall, Tamas Szakmany, Sanjoy Shah, Karen Kempsell, Graham Ball
-
Patent number: 11850264Abstract: The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or immunogenic agent or bispecific or vaccine comprising said TCR, said cell, said clone or said vector; said TCR or said cell or said clone or said vector or said pharmaceutical composition or immunogenic agent or bispecific or vaccine for use in the treatment of cancer; a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition, immunogenic agent, bispecific or vaccine comprising said TCR; and a ligand with which said TCR binds.Type: GrantFiled: May 19, 2020Date of Patent: December 26, 2023Assignee: University College Cardiff Consultants Ltd.Inventors: Andrew Sewell, Garry Dolton
-
Patent number: 11768264Abstract: A method for multi-dimensional, relaxation-diffusion magnetic resonance fingerprinting (MRF) includes performing, using a magnetic resonance imaging (MRI) system, a pulse sequence that integrates free-waveform b-tensor diffusion encoding into a magnet resonance fingerprinting pulse sequence to perform a multi-dimensional, relaxation-diffusion encoding while acquiring MRF signal evolutions, processing, using a processor, the acquired MRF signal evolutions to determine at least one relaxation parameter and at least one diffusivity parameter, and generating, using the processor, a report including at least one of the at least one relaxation parameter and the at least diffusivity parameter.Type: GrantFiled: May 2, 2022Date of Patent: September 26, 2023Assignees: Case Western Reserve University, University College Cardiff Consultants Limited CardiffInventors: Dan Ma, Mark A. Griswold, Derek Jones, Maryam Afzali, Lars Mueller
-
Publication number: 20230270985Abstract: The invention concerns a device for introducing microneedles into the skin of a subject; and a method for inserting microneedles into the skin of a subject comprising use of said device.Type: ApplicationFiled: July 1, 2021Publication date: August 31, 2023Applicant: University College Cardiff Consultants LimitedInventors: James Birchall, Sion Coulman, Benedetta Gualeni, Oliver Bishop, Nicholas Smart, Isabelle Stauber
-
Publication number: 20230263619Abstract: The invention concerns a device for use in ligament surgery to locate the best graft attachment site, including parts thereof; a kit of parts for use in ligament surgery; and a method for performing ligament surgery.Type: ApplicationFiled: October 8, 2020Publication date: August 24, 2023Applicant: University College Cardiff Consultants LimitedInventors: Peter Simon Theobald, Mohamed Mahmoud Elfekky
-
Patent number: 11725039Abstract: The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or bispecific comprising said TCR, said cell, said clone or said vector; use of said TCR or said cell or said clone or said vector or said pharmaceutical composition or bispecific to treat cancer; and a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition or bispecific comprising said TCR.Type: GrantFiled: April 24, 2020Date of Patent: August 15, 2023Assignee: University College Cardiff Consultants Ltd.Inventors: Andrew Sewell, Garry Dolton
-
Patent number: 11669059Abstract: Certain aspects of the present disclosure provide techniques for semantically contextualizing structured and unstructured data, extracting and making sense of domain knowledge, and performing semantic-driven optimization to provide generic, scalable, autonomous and real-time performance management within a built environment domain.Type: GrantFiled: July 16, 2019Date of Patent: June 6, 2023Assignee: UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (UC3)Inventors: Yacine Rezgui, Thomas Henry Outram Beach, Ioan Petri, Jean-Laurent Hippolyte, Muhammad Waseem Ahmad, Wanqing Zhao, Shaun Howell
-
Patent number: 11471502Abstract: Inhibitors of MAPK3 (ERK1 MAP kinase), in particular polypeptides having the ability to stimulate the global ERK signalling pathway in the brain and their use as neuroprotective and/or cognitive enhancing agents, are disclosed. Related polynucleotides, vectors, host cells and pharmaceutical compositions able to inhibit MAPK3, causing the stimulation of the global ERK signalling pathway, are also disclosed. Additionally, use of the afore inhibitors or stimulators in the treatment of neurodegenerative or neuropsychiatric disorders and cognitive impairment is also disclosed.Type: GrantFiled: November 23, 2018Date of Patent: October 18, 2022Assignee: University College Cardiff Consultants LtdInventors: Riccardo Brambilla, Stefania Fasano, Marzia Indrigo, Alessandro Papale
-
Publication number: 20220249162Abstract: The present disclosure provides a medical device (100) for inducing cell death in cancer cells. The device comprises a signal generator (102) arranged to generate a pulsed electrical signal, and a transmitter (116) arranged to receive the pulsed electrical signal and generate, in response to the electrical signal, an electric field in a treatment volume. The device (100) is arranged such that the pulsed electrical signal received by the transmitter (116) has a pulse width of 0.1 microsecond to 1 millisecond, and a signal frequency of 10 Megahertz to 20 Gigahertz. The present disclosure also provides a method of inducing cell death. The method comprising a step of generating, using a transmitter (116), a pulsed time varying electric field in a treatment volume comprising a volume of cells to be treated. The electric field has a pulse width of 0.1 microsecond to 1 millisecond, and a signal frequency of 10 Megahertz to 20 Gigahertz.Type: ApplicationFiled: May 1, 2020Publication date: August 11, 2022Applicant: University College Cardiff Consultants LimitedInventors: Johannes BENEDIKT, Robert Edward MANSEL, Wen Guo JIANG, Tracey Amanda MARTIN, Philippa YOUNG
-
Publication number: 20220227861Abstract: The invention relates to an anti-mitotic agent comprising at least one antibody, or an epitope thereof, that selectively binds the extracellular domain of at least one ZIP (Zrt, Irt-like Proteins) transporter protein to inhibit its function, specifically mitosis; a composition comprising same; and the use of said anti-mitotic agent or composition to treat a hyper proliferative disorder including cancer.Type: ApplicationFiled: June 5, 2020Publication date: July 21, 2022Applicant: University College Cardiff Consultants LimitedInventor: Kathryn Taylor
-
Publication number: 20220193663Abstract: The invention concerns a novel acoustofluidic device to separate acoustically active particles from fluids comprising a novel device arrangement for improved acoustic pressure and particle velocity; and a method of separating particles from a fluid comprising use of same.Type: ApplicationFiled: March 26, 2020Publication date: June 23, 2022Applicant: University College Cardiff Consultants LimitedInventor: Xin Yang
-
Patent number: 11298345Abstract: The invention provides compounds of the formula (I): (I) wherein A1, A2, R2, R4, B1, B2, X, X1, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.Type: GrantFiled: March 1, 2019Date of Patent: April 12, 2022Assignee: University College Cardiff Consultants LimitedInventors: Simon Ward, Paul Beswick, Lewis Pennicott, Tristan Reuillon, Irina Chuckowree, Carolina Villalonga-Barber, Roderick Alan Porter
-
Patent number: 11294018Abstract: Microwave resonance cavities and associated methods and apparatus are described. In one example, a cavity (100) comprises a first and a second input port (102, 104) for inputting microwave radiation at a first and a second frequency respectively. The microwave radiation at the first frequency may be to excite a sample in the cavity whereas the microwave radiation at the second frequency may be to interrogate a sample in the cavity for analysis. The cavity has dimensions such that it resonates at both the first and the second frequency.Type: GrantFiled: August 21, 2018Date of Patent: April 5, 2022Assignee: University College Cardiff Consultants LimitedInventors: Adrian Porch, Damien Murphy
-
Patent number: 11207687Abstract: The invention relates to an artificial cell system comprising at least one droplet-interface bilayer (DIB) encased within a shell; a suspension comprising same; and a method and a device for the manufacture of same.Type: GrantFiled: September 15, 2017Date of Patent: December 28, 2021Assignee: UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTDInventors: Oliver Castell, David Barrow, Divesh Baxani
-
Patent number: 11186567Abstract: The invention provides compounds of the formula (I): wherein R1 and R2 are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.Type: GrantFiled: February 9, 2018Date of Patent: November 30, 2021Assignee: University College Cardiff Consultants LimitedInventors: Simon Ward, Paul Beswick, Lewis Pennicott, Tristan Reuillon
-
Patent number: 11180466Abstract: The invention relates to a compound of general formula (I): wherein R1, R2, R3, R4, Q, m and n are as defined herein. The compounds are inhibitors of Bcl-3 and are useful for the treatment of cancer, particularly metastatic cancer.Type: GrantFiled: October 4, 2019Date of Patent: November 23, 2021Assignee: UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITEDInventors: Andrew David Westwell, Andrea Brancale, Richard William Ernest Clarkson, Jitka Soukupova
-
Publication number: 20210349158Abstract: An SOP for connection to a first feeder in an electricity distribution network, the SOP being configured to, when a feeder connected to the SOP is faulty, apply a diagnostic voltage to the feeder and make current and voltage measurements at the connection of the SOP to the feeder while the diagnostic voltage is being applied.Type: ApplicationFiled: October 9, 2019Publication date: November 11, 2021Applicant: University College Cardiff Consultants LtdInventors: Jianzhong WU, Avinash AITHAL
-
Patent number: 11083696Abstract: The invention concerns a cartridge for an inhalation device for delivering anaesthetic to a human or animal wherein anaesthetic in said cartridge is dispersed in an anaesthetic control release medium; an inhalation device for use with said cartridge and a formulation comprising at least one selected anaesthetic and anaesthetic control release medium.Type: GrantFiled: October 20, 2017Date of Patent: August 10, 2021Assignee: University College Cardiff Consultants LimitedInventors: Judith Hall, Alison Paul, Antony Wilkes
-
Patent number: 11078221Abstract: Compounds of general formula (I): (Formula I)) wherein R1, Q, R3, R4, R5, R6, R7 and Ar1 are as defined herein are inhibitors of class I histone deacetylases and are of use in the treatment of lysosomal storage disorders, especially Niemann-Pick type C disease, as well as other lysosomal storage disorders, defective autophagy, accumulation of free cholesterol and mycobacterial diseases.Type: GrantFiled: September 28, 2018Date of Patent: August 3, 2021Assignee: UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTDInventors: Emyr Lloyd-Evans, Fabrizio Pertusati, Edward James, Emily Maguire, Christopher McGuigan